The Cutaneous Mycosis drugs in development market research report provides comprehensive information on the therapeutics under development for Cutaneous Mycosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Cutaneous Mycosis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Cutaneous Mycosis and features dormant and discontinued products.
GlobalData tracks 17 drugs in development for Cutaneous Mycosis by 17 companies/universities/institutes. The top development phase for Cutaneous Mycosis is phase ii with six drugs in that stage. The Cutaneous Mycosis pipeline has 16 drugs in development by companies and one by universities/ institutes. Some of the companies in the Cutaneous Mycosis pipeline products market are: Blueberry Therapeutics, Almirall and Photonamic.
The key targets in the Cutaneous Mycosis pipeline products market include Squalene Monooxygenase (Squalene Epoxidase or SQLE or EC 1.14.14.17), Cell Membrane, and Lanosterol 14 Alpha Demethylase (Sterol 14 Alpha Demethylase or Cytochrome P450 14DM or Cytochrome P450LI or Cytochrome P450 51A1 or CYPLI or CYP51A1 or EC 1.14.14.154).
The key mechanisms of action in the Cutaneous Mycosis pipeline product include Squalene Monooxygenase (Squalene Epoxidase or SQLE or EC 1.14.14.17) Inhibitor with five drugs in Phase III. The Cutaneous Mycosis pipeline products include four routes of administration with the top ROA being Topical and one key molecule types in the Cutaneous Mycosis pipeline products market including Small Molecule.
Cutaneous Mycosis overview
Cutaneous mycoses are a group of superficial fungal infections that affect the skin, hair, and nails. They are also known as superficial mycoses. They are confined to the outer layers of the skin, hair, or nails. They rarely invade deeper tissues or viscera, and do not induce a cellular response from the host. Most cutaneous mycoses are caused by dermatophytes, a group of filamentous fungi that colonize and infect keratinized tissues, including the outermost layer of skin.
For a complete picture of Cutaneous Mycosis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
